Colorado Medtech buys Creos
Imaging OEM component provider Colorado Medtech has added to its medical imaging portfolio with the acquisition of Creos Technologies, an Englewood, CO-based provider of x-ray generator subsystems. Boulder, CO-based Colorado Medtech purchased Creos for
Imaging OEM component provider Colorado Medtech has added to its medical imaging portfolio with the acquisition of Creos Technologies, an Englewood, CO-based provider of x-ray generator subsystems. Boulder, CO-based Colorado Medtech purchased Creos for $2 million and plans to integrate the assets into its Imaging and Power Systems division, which designs and develops MRI components and systems for OEMs. Colorado Medtech also develops and manufactures electromechanical assemblies and software for ultrasound, CT, x-ray, and nuclear medicine systems.
In a related story, a Colorado Tech student buys Oreos.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
